Baseline Assessment

Please answer these questions to assess your knowledge and decision‑making in identifying, diagnosing, and managing GEP‑NETs across imaging, pathology, surgery, systemic therapies, and team‑based care.
Mintallah Haider, MD

Medical Oncology Neuroendocrine Tumor Program - Department of Gastrointestinal Oncology,
Moffitt Cancer Center
Tampa, FL

Dr. Haider is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center and an Associate Professor of Oncologic Sciences at University of South Florida. Dr. Haider’s clinical practice is focused on neuroendocrine tumor (NET) oncology. As a member of the Endocrine Program Multidisciplinary team, she also treats paraganglioma and pheochromocytoma. In parallel, Dr. Haider leads and participates in clinical research focused on the systemic therapies of these tumors. As a Clinical Educator, she participates in the education of medical students, residents, and fellows as well as community outreach. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), where she serves on the Continuing Education Committee and has been an invited moderator and speaker at NANETS national and regional seminars.

Chandrikha Chandrasekharan, MBBS

Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. Her clinical practice focuses on neuroendocrine tumors and pancreatic cancer, and she is dual board-certified in Medical Oncology and Palliative Medicine. Before joining MD Anderson in 2025, Dr. Chandrasekharan served for eight years on faculty at the University of Iowa, where she co-led the gastrointestinal oncology program and helped lead the Clinical Core for the Neuroendocrine Tumor SPORE (2021–2022). An active member of the North American Neuroendocrine Tumor Society (NANETS), she regularly contributes to education and multidisciplinary care initiatives for the NET community.

1.
IDENTIFY the diverse clinical presentations and sites of origin of NETs/GEP-NETs to improve early diagnosis rates.
2.
INTERPRET the importance of functional versus nonfunctional NETs in patient assessment and management plans.
3.
APPLY the latest diagnostic guidelines and procedures for NETs/GEP-NETs to enhance patient outcomes.
4.
EVALUATE the role of surgery in managing NETs/GEP-NETs and the criteria for choosing between curative and palliative approaches.
5.
ASSESS efficacy and sequencing of systemic therapies, including somatostatin analogues and PRRT, in the treatment plan for NETs.
6.
EVALUATE factors influencing treatment sequencing decisions for NET/GEP-NETs, including tumor characteristics (grade, burden, progression rate), symptom management, previous treatment responses, patient preferences, QoL considerations, and nutritional status.
7.
UNDERSTAND roles of various specialists (endocrinologists, oncologists, surgeons, radiologists, dieticians etc.) within the multidisciplinary team and the importance of collaboration in optimizing NETs/GEP-NETs management.
8.
ANALYZE clinical trial data and evidence-based recommendations for emerging treatments in the management of patients with NETs/GEP-NETs.
9.
DEVELOP strategies for the prompt and effective integration of novel therapies into treatment protocols for NETs/GEP-NETs.